Pancreatic Cancer Research

ResearcherBeijing University of Chinese MedicineActive in the last 2 years

Yonggang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0096-9033; OpenAlex author ID A5058548677. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
5
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Harmine suppresses pancreatic cancer through DYRK1A-mediated hyper-activated RAS/MAPK inhibition. Last author DOI 10.1016/j.bcp.2025.117291↗
  2. Coptisine suppresses proliferation and inhibits metastasis in human pancreatic cancer PANC-1 cells. Co-author DOI 10.1080/10286020.2019.1585820↗
  3. Isorhamnetin suppresses PANC-1 pancreatic cancer cell proliferation through S phase arrest. Last author DOI 10.1016/j.biopha.2018.09.105↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xia Li · 1 shared paper, 2025 · strength 0.27
  2. Cen Liu · 1 shared paper, 2025 · strength 0.27
  3. Peng Tan · 1 shared paper, 2020 · strength 0.12
  4. Yali Zhang · 1 shared paper, 2020 · strength 0.12
  5. Jiali Wang · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.